Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2001

View Archived Issues

Scios completes preliminary clinical trial of SCIO-469, its p38 kinase inhibitor

Xenogen and Pfizer establish genetic modification collaboration

MacroChem begins open-label continuation phase III study of Topiglan

Cypress Bioscience and Fresenius restructure Prosorba agreement

Clinical evaluation of Envision TD for DME and posterior uveitis continues

AstraZeneca discontinues development of Zendra

In vivo evidence for alpha1A-adrenoceptor and prostate selectivity of KMD-3213

Chronic treatment with ETA antagonist markedly reduces morbidity and mortality in rat model

NDA for abarelix depot officially filed by FDA; drug assigned priority review status

FDA accepts Amylin's Symlin NDA for review

GenVec provides update on collaborative efforts with Warner-Lambert (Pfizer)

Actos may now be prescribed in U.K. for the management of type 2 diabetes

Dyax's EPI-HNE-4 well tolerated in phase Ib; Debiopharm gains commercialization rights

Actiq introduced in U.K. for patients with breakthrough pain

Safety issue restricts Pfizer capravirine trials

Studies explore mechanism of glucose-dependent insulinotropic effects of JTT-608

Isotechnika's ISAtx-247 to be developed for third indication: psoriasis

New company formed by Inex to develop gene delivery technology

Pfizer extends asthma/allergy drug discovery alliance with Rigel

New Isis antisense compounds modulate hnRNP A1 expression

Tricyclic analgesics and their use in the treatment of pain claimed in recent patent

FR-167653 used to determine role of p38 kinase in H. pylori gastritis

Bone-stimulating factors under evaluation at Osteopharm

Neurim team discovers new melatonin-related compounds with unique profile

Antiviral and antitumor thymine derivatives described in recent patent

Canadian company describes new hexapeptides acting as CCR3 receptor antagonists

DuPont's newest compounds for HIV infection

Apoptosis inducers emerge from R&D at Nippon Kayaku

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...